Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.

Blood - 1 Aug 2001

Levis M, Tse K F, Smith B D, Garrett E, Small D

Abstract excerpt

Internal tandem duplication (ITD) mutations of the receptor tyrosine kinase FLT3 have been found in 20% to 30% of patients with acute myeloid leukemia (AML). These mutations constitutively activate the receptor and appear to be associated with a poor prognosis. Recent evidence that this constitut...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease
Share to Enzyme Inhibitors
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid

Share to Protein-Tyrosine Kinases

Share to Receptor Protein-Tyrosine Kinases

Share to Tandem Repeat Sequences

Share to Tyrphostins

Source

Identifiers

PMID: 11468194
DOI: 10.1182/blood.v98.3.885

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-11468194-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.PMID 11468194Read ↗

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.Semantic proximity Read ↗

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosisSemantic proximity Read ↗

Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities.Semantic proximity Read ↗

The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases.Semantic proximity Read ↗

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivoSemantic proximity Read ↗

Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.Semantic proximity Read ↗

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.Semantic proximity Read ↗

Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment.Semantic proximity Read ↗

Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD+ acute myeloid leukemia.Semantic proximity Read ↗

Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.Semantic proximity Read ↗

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.Semantic proximity Read ↗

The expression of P‐glycoprotein in AML cells with <i>FLT3</i> internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.